Replies to post #122209 on Biotech Values

[masterlongevity]

pre-clinical data for c-terminus directed antibodies is not as good as for n-terminus directed antibodies targeting AB.

I personally don't think this is going to work. The strongest antibody candidate seems to be bapineuzumab. If it doesn't work, i don't think any of the other anti-amyloid candidates will (at least in Mild to moderate disease)

[genisi]

Ponezumab (PF-04360365)

There were 3 posters (PK/PD, safety, and biomarkers) at ICAD 2010. This is the interesting one imo:

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=d04410b9-4beb-45cb-b405-4ea01bbf7bfa&cKey=f4c38166-98c9-4540-8905-12d48a5fc763&mKey={7C4F47AC-AD99-45B7-970B-F8414FE3AD4F}